Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis

Company Overview

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) is a Canadian clinical-stage biotechnology company focused on developing locally delivered therapies designed to treat disease at the site of action while potentially reducing systemic exposure and associated side effects. The company is headquartered in Victoria, British Columbia, and is developing candidates for inflammatory and other serious medical conditions.

Eupraxia’s lead program, EP-262, is an extended-release formulation of dexamethasone being developed for the treatment of pain and inflammation associated with osteoarthritis of the knee. The company’s approach is intended to provide sustained drug delivery within the affected joint and is based on its proprietary DiffuSphere technology.

The company has also developed EP-7041, an investigational small-molecule inhibitor of factor XIa being evaluated for its potential use in preventing and treating blood clots. Eupraxia does not currently have marketed products and remains focused on research, clinical development and potential commercialization through regulatory approval and strategic partnerships.

Key Stats

• Today's Range: $7.07 to $7.93
• 50-Day Range: $5.97 to $9.10
• 52-Week Range: $5.25 to $9.32
• Volume: 1.77 million shs
• Average Volume: 706,693 shs
• Market Capitalization: $503.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.80
• Consensus Rating: Moderate Buy

Eupraxia Pharmaceuticals Stock Analysis - MarketRank™

Eupraxia Pharmaceuticals scored higher than 47% of companies evaluated by MarketBeat, and ranked 536th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Eupraxia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 2 strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Eupraxia Pharmaceuticals has a consensus price target of $17.80, representing about 130.0% upside from its current price of $7.74.

Amount of Analyst Coverage

Eupraxia Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Eupraxia Pharmaceuticals are expected to decrease in the coming year, from ($0.85) to ($0.99) per share.

Price to Book Value per Share Ratio

Eupraxia Pharmaceuticals has a P/B Ratio of 5.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.66% of the float of Eupraxia Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 11.25, which indicates bearish sentiment.

Change versus previous month

Short interest in Eupraxia Pharmaceuticals has recently increased by 6.61%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eupraxia Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eupraxia Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.52

News Sentiment

Eupraxia Pharmaceuticals has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Eupraxia Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for EPRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eupraxia Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Institutions

Eupraxia Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EPRX
• Previous Symbol: NASDAQ:EPRX
• CIK: 1581178
• Web: www.eupraxiapharma.com
• Phone: 250-590-3968
• Fax: N/A
• Employees: 49
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Eupraxia Pharmaceuticals: $17.80
• High Price Target: $25.00
• Low Price Target: $11.00
• Potential Upside/Downside: +130.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.58 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -63.97%
• Return on Assets: -43.32%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 16.00
• Quick Ratio: 16.00

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.41 per share
• Price / Book: 5.49

Miscellaneous

• Outstanding Shares: 65,020,000
• Free Float: N/A
• Market Cap: $503.25 million
• Optionable: N/A
• Beta: 0.83